High-Density Lipoprotein Subfractions: Much Ado About Nothing or Clinically Important?

Overview

Journal Biomedicines

Specialty Biomedical Engineering

Date 2021 Aug 6

PMID 34356900

Citations 8

Authors

Knut Tore Lappegard

Christian Abendstein Kjellmo

Anders Hovland

Affiliations

Soon will be listed here.

Abstract

High-density lipoproteins (HDL) are a heterogenous group of plasma molecules with a large variety in composition. There is a wide specter in lipid content and the number of different proteins that has been associated with HDL is approaching 100. Given this heterogeneity and the fact that the total amount of HDL is inversely related to the risk of coronary heart disease (CHD), there has been increasing interest in the function of specific HDL subgroups and in what way measuring and quantifying these subgroups could be of clinical importance in determining individual CHD risk. If certain subgroups appear to be more protective than others, it may also in the future be possible to pharmacologically increase beneficial and decrease harmful subgroups in order to reduce CHD risk. In this review we give a short historical perspective, summarize some of the recent clinical findings regarding HDL subclassifications and discuss why such classification may or may not be of clinical relevance.

Citing Articles

HDL Levels as a Novel Predictor of Long-Term Adverse Outcomes in Patients with Heart Failure: A Retrospective Cohort Study.

Abudouwayiti A, Yisimayili S, Tuersun R, Aimaier S, Yisha D, Zhang X J Inflamm Res. 2024; 17:6251-6264.

PMID: 39286819 PMC: 11403014. DOI: 10.2147/JIR.S481085.

Association between HDL-C and intensive blood pressure control in patients with hypertension: A post-hoc analysis of SPRINT.

Liu R, Cheng W J Clin Hypertens (Greenwich). 2024; 26(3):225-234.

PMID: 38318688 PMC: 10918727. DOI: 10.1111/jch.14754.

A decreased level of high-density lipoprotein is a possible risk factor for type 2 diabetes mellitus: A review.

Bodaghi A, Ebadi E, Gholami M, Azizi R, Shariati A Health Sci Rep. 2023; 6(12):e1779.

PMID: 38125279 PMC: 10731824. DOI: 10.1002/hsr2.1779.

Association of HDL Subfraction Profile with the Progression of Insulin Resistance.

Piko P, Jenei T, Kosa Z, Sandor J, Kovacs N, Seres I Int J Mol Sci. 2023; 24(17).

PMID: 37686368 PMC: 10488248. DOI: 10.3390/ijms241713563.

Association between Lipoprotein Subfractions, Hemostatic Potentials, and Coronary Atherosclerosis.

Poropat Flerin T, Bozic Mijovski M, Jug B Dis Markers. 2022; 2022:2993309.

PMID: 36082237 PMC: 9448618. DOI: 10.1155/2022/2993309.

References

Khera A, Demler O, Adelman S, Collins H, Glynn R, Ridker P . Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin). Circulation. 2017; 135(25):2494-2504. PMC: 5490983. DOI: 10.1161/CIRCULATIONAHA.116.025678. View

Ohtani R, Nirengi S, Nakamura M, Murase N, Sainouchi M, Kuwata Y . High-Density Lipoprotein Subclasses and Mild Cognitive Impairment: Study of Outcome and aPolipoproteins in Dementia (STOP-Dementia)1. J Alzheimers Dis. 2018; 66(1):289-296. DOI: 10.3233/JAD-180135. View

Gluba-Brzozka A, Franczyk B, Banach M, Rysz-Gorzynska M . Do HDL and LDL subfractions play a role in atherosclerosis in end-stage renal disease (ESRD) patients?. Int Urol Nephrol. 2016; 49(1):155-164. DOI: 10.1007/s11255-016-1466-x. View

Ridker P, Danielson E, Fonseca F, Genest J, Gotto Jr A, Kastelein J . Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195-207. DOI: 10.1056/NEJMoa0807646. View

Trinder M, Wang Y, Madsen C, Ponomarev T, Bohunek L, Daisely B . Inhibition of Cholesteryl Ester Transfer Protein Preserves High-Density Lipoprotein Cholesterol and Improves Survival in Sepsis. Circulation. 2020; 143(9):921-934. DOI: 10.1161/CIRCULATIONAHA.120.048568. View

Hunter W, McGarrah 3rd R, Kelly J, Khouri M, Craig D, Haynes C . High-Density Lipoprotein Particle Subfractions in Heart Failure With Preserved or Reduced Ejection Fraction. J Am Coll Cardiol. 2019; 73(2):177-186. DOI: 10.1016/j.jacc.2018.10.059. View

Armitage J, Holmes M, Preiss D . Cholesteryl Ester Transfer Protein Inhibition for Preventing Cardiovascular Events: JACC Review Topic of the Week. J Am Coll Cardiol. 2019; 73(4):477-487. PMC: 6354546. DOI: 10.1016/j.jacc.2018.10.072. View

Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M . Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a long-term perspective. Eur Heart J. 2015; 36(19):1163-70. DOI: 10.1093/eurheartj/ehu505. View

Hovland A, Jonasson L, Garred P, Yndestad A, Aukrust P, Lappegard K . The complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosis. Atherosclerosis. 2015; 241(2):480-94. DOI: 10.1016/j.atherosclerosis.2015.05.038. View

10.

Kummen M, Mayerhofer C, Vestad B, Broch K, Awoyemi A, Storm-Larsen C . Gut Microbiota Signature in Heart Failure Defined From Profiling of 2 Independent Cohorts. J Am Coll Cardiol. 2018; 71(10):1184-1186. DOI: 10.1016/j.jacc.2017.12.057. View

11.

CASTELLI W, DOYLE J, Gordon T, HAMES C, Hjortland M, Hulley S . HDL cholesterol and other lipids in coronary heart disease. The cooperative lipoprotein phenotyping study. Circulation. 1977; 55(5):767-72. DOI: 10.1161/01.cir.55.5.767. View

12.

Carnuta M, Stancu C, Toma L, Sanda G, Niculescu L, Deleanu M . Dysfunctional high-density lipoproteins have distinct composition, diminished anti-inflammatory potential and discriminate acute coronary syndrome from stable coronary artery disease patients. Sci Rep. 2017; 7(1):7295. PMC: 5544737. DOI: 10.1038/s41598-017-07821-5. View

13.

Kidawa M, Gluba-Brzozka A, Zielinska M, Franczyk B, Banach M, Rysz J . Cholesterol Subfraction Analysis in Patients with Acute Coronary Syndrome. Curr Vasc Pharmacol. 2018; 17(4):365-375. DOI: 10.2174/1570161116666180601083225. View

14.

Vaisar T, Kanter J, Wimberger J, Irwin A, Gauthier J, Wolfson E . High Concentration of Medium-Sized HDL Particles and Enrichment in HDL Paraoxonase 1 Associate With Protection From Vascular Complications in People With Long-standing Type 1 Diabetes. Diabetes Care. 2019; 43(1):178-186. PMC: 6925582. DOI: 10.2337/dc19-0772. View

15.

Rosenson R, Brewer Jr H, Chapman M, Fazio S, Hussain M, Kontush A . HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem. 2011; 57(3):392-410. DOI: 10.1373/clinchem.2010.155333. View

16.

Zitnanova I, Oravec S, Janubova M, Konarikova K, Dvorakova M, Laubertova L . Gender differences in LDL and HDL subfractions in atherogenic and nonatherogenic phenotypes. Clin Biochem. 2020; 79:9-13. DOI: 10.1016/j.clinbiochem.2020.02.002. View

17.

Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, Halsey J . Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet. 2007; 370(9602):1829-39. DOI: 10.1016/S0140-6736(07)61778-4. View

18.

Varela L, Meseguer E, Lapergue B, Couret D, Amarenco P, Meilhac O . Changes in High-Density Lipoproteins Related to Outcomes in Patients with Acute Stroke. J Clin Med. 2020; 9(7). PMC: 7408777. DOI: 10.3390/jcm9072269. View

19.

Christensen J, Ulven S, Retterstol K, Narverud I, Bogsrud M, Henriksen T . Comprehensive lipid and metabolite profiling of children with and without familial hypercholesterolemia: A cross-sectional study. Atherosclerosis. 2017; 266:48-57. DOI: 10.1016/j.atherosclerosis.2017.09.021. View

20.

Munoz-Hernandez L, Ortiz-Bautista R, Brito-Cordova G, Lozano-Arvizu F, Saucedo S, Perez-Mendez O . Cholesterol efflux capacity of large, small and total HDL particles is unaltered by atorvastatin in patients with type 2 diabetes. Atherosclerosis. 2018; 277:72-79. DOI: 10.1016/j.atherosclerosis.2018.08.027. View